Advanced Search:
Equity Index Forex Crypto Commodity

SCYX - SCYNEXIS

$1.69  -0.13 (-7.14%)

Updated: 22:55 Apr 30, 2024 EST

Next Hour's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Session's AI Forecast

N/A

Avg. Accuracy (AI)

N/A

Next Week's AI Forecast

N/A

Trend's Accuracy (AI)

N/A

SCYNEXIS's Position Within the Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

SCYNEXIS - HISTORICAL DATA 6M

  • Last price

    $ 1.69

  • Daily change

    $ -0.13

  • Previous Close

    $ 1.82

  • Last Updated

    22:55 Apr 30, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 0.32 -0.21 0.03 -0.27

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 4.93 3.62 3.17 3.6

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A 53.57% 68.67% 69.77%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0 -100% 1.57 3.29% 1.52 -11.63% 1.72

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.5 42.2 1.33 33.33

SCYNEXIS Technical Analysis News

SCYNEXIS

1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302-6548
United States
201 884 5485
https://www.scynexis.com

Description

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Corporate Governance

SCYNEXIS, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

SCYNEXIS'S HOLDERS RANK

List of holders with stock participation in SCYNEXIS.

Holder Rank Holder Shares Date Reported % Out Value